Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Hegde

Showing results (601-610 of 657) with videos related to

Pageof 66
Sort By:
Journal of Cardiovascular Pharmacology|February 8, 2011
Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the ratLaxminarayan G Hegde, Cecile Yu, Travis Renner, et al.
ACS Medicinal Chemistry Letters|January 19, 2019
Discovery of TD-0212, an Orally Active Dual Pharmacology AT<sub>1</sub> Antagonist and Neprilysin Inhibitor (ARNI)R Murray McKinnell, Paul Fatheree, Seok-Ki Choi, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 2, 2016
Th17 Responses to Collagen Type V, kα1-Tubulin, and Vimentin Are Present Early in Human Development and Persist Throughout LifeJ A Sullivan, E Jankowska-Gan, S Hegde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia StudyDavid F McDermott, Jeffrey A Sosman, Mario Sznol, et al.
Infection and Immunity|January 25, 2017
Identification of Mycobacterial RplJ/L10 and RpsA/S1 Proteins as Novel Targets for CD4<sup>+</sup> T CellsAlison J Johnson, Steven C Kennedy, Cecilia S Lindestam Arlehamn, et al.
Nature|November 28, 2014
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerThomas Powles, Joseph Paul Eder, Gregg D Fine, et al.
Nature Communications|February 15, 2024
The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylationChristopher B Nelson, Samuel Rogers, Kaushik Roychoudhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of AtezolizumabOmid Hamid, Luciana Molinero, Christopher R Bolen, et al.
Cancer Chemotherapy and Pharmacology|June 16, 2018
Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumorsColin D Weekes, Lee S Rosen, Anna Capasso, et al.
Plos One|June 8, 2018
Interrogation of transcriptomic changes associated with drug-induced hepatic sinusoidal dilatation in colorectal cancerMonika A Jarzabek, William R Proctor, Jennifer Vogt, et al.
Pageof 66

Showing results (601-610 of 657) with videos related to

Sort By:
Pageof 66
Journal of Cardiovascular Pharmacology|February 8, 2011
Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the ratLaxminarayan G Hegde, Cecile Yu, Travis Renner, et al.
ACS Medicinal Chemistry Letters|January 19, 2019
Discovery of TD-0212, an Orally Active Dual Pharmacology AT<sub>1</sub> Antagonist and Neprilysin Inhibitor (ARNI)R Murray McKinnell, Paul Fatheree, Seok-Ki Choi, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 2, 2016
Th17 Responses to Collagen Type V, kα1-Tubulin, and Vimentin Are Present Early in Human Development and Persist Throughout LifeJ A Sullivan, E Jankowska-Gan, S Hegde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia StudyDavid F McDermott, Jeffrey A Sosman, Mario Sznol, et al.
Infection and Immunity|January 25, 2017
Identification of Mycobacterial RplJ/L10 and RpsA/S1 Proteins as Novel Targets for CD4<sup>+</sup> T CellsAlison J Johnson, Steven C Kennedy, Cecilia S Lindestam Arlehamn, et al.
Nature|November 28, 2014
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerThomas Powles, Joseph Paul Eder, Gregg D Fine, et al.
Nature Communications|February 15, 2024
The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylationChristopher B Nelson, Samuel Rogers, Kaushik Roychoudhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of AtezolizumabOmid Hamid, Luciana Molinero, Christopher R Bolen, et al.
Cancer Chemotherapy and Pharmacology|June 16, 2018
Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumorsColin D Weekes, Lee S Rosen, Anna Capasso, et al.
Plos One|June 8, 2018
Interrogation of transcriptomic changes associated with drug-induced hepatic sinusoidal dilatation in colorectal cancerMonika A Jarzabek, William R Proctor, Jennifer Vogt, et al.
Pageof 66